{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:27:47Z","timestamp":1782534467125,"version":"3.54.5"},"reference-count":177,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.semnephrol.2014.04.005","type":"journal-article","created":{"date-parts":[[2014,4,18]],"date-time":"2014-04-18T12:40:41Z","timestamp":1397824841000},"page":"285-306","source":"Crossref","is-referenced-by-count":30,"title":["Comparison of Agents That Affect Aldosterone Action"],"prefix":"10.1016","volume":"34","author":[{"given":"Juan","family":"Tamargo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Solini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis M.","family":"Ruilope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2014.04.005_bib1","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.108.119966","article-title":"Reconsidering the roles of the mineralocorticoid receptor","volume":"53","author":"Funder","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib2","doi-asserted-by":"crossref","first-page":"B4","DOI":"10.1093\/eurheartj\/sur004","article-title":"Aldosterone and the mineralocorticoid receptor","volume":"13","author":"Messaoudi","year":"2011","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/nrneph.2013.110","article-title":"Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis","volume":"9","author":"Brown","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib4","first-page":"1","article-title":"Aldosterone, hypertension, and cardiovascular disease","volume":"52","author":"Ruilope","year":"2008","journal-title":"An endless story. Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib5","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1093\/eurheartj\/ehs257","article-title":"Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice","volume":"33","author":"Zannad","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/00041552-200303000-00006","article-title":"Aldosterone in renal disease","volume":"12","author":"Ibrahim","year":"2003","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7326\/0003-4819-150-11-200906020-00005","article-title":"Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension","volume":"150","author":"Sowers","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib8","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1210\/jc.2003-030490","article-title":"50th anniversary of aldosterone","volume":"88","author":"Williams","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib9","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.mce.2011.06.038","article-title":"Aldosterone, mineralocorticoid receptor, and heart failure","volume":"350","author":"Messaoudi","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib10","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/joe.1.06017","article-title":"The new biology of aldosterone","volume":"186","author":"Connell","year":"2002","journal-title":"J Endocrinol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib12","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3317\/jraas.2003.025","article-title":"Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease","volume":"4","author":"Pitt","year":"2003","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib13","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.108.117531","article-title":"Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling","volume":"52","author":"Di Zhang","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1006\/bbrc.1995.2106","article-title":"Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C alpha","volume":"213","author":"Christ","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib15","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mce.2009.02.005","article-title":"New aspects of rapid aldosterone signaling","volume":"308","author":"Grossmann","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1530\/JOE-11-0372","article-title":"Mechanism of ligand specificity of the mineralocorticoid receptor","volume":"213","author":"Fuller","year":"2012","journal-title":"J Endocrinol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrneph.2010.30","article-title":"Aldosterone effects on the kidney and cardiovascular system","volume":"6","author":"Briet","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib18","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11906-011-0182-2","article-title":"The role of aldosterone in metabolic syndrome","volume":"13","author":"Briet","year":"2011","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib19","doi-asserted-by":"crossref","first-page":"F181","DOI":"10.1152\/ajprenal.2001.280.2.F181","article-title":"Multiple aspects of mineralocorticoid selectivity","volume":"280","author":"Farman","year":"2001","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib20","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib21","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib22","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1210\/endo-97-1-52","article-title":"Antiandrogenic effect of spirolactones: mechanism of action","volume":"97","author":"Corvol","year":"1975","journal-title":"Endocrinology"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib24","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","article-title":"Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis","volume":"10","author":"Sica","year":"2005","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1751-7176.2010.00377.x","article-title":"Treatment considerations with aldosterone receptor antagonists","volume":"13","author":"Sica","year":"2011","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib27","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","article-title":"Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"De Gasparo","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","article-title":"The evolution of aldosterone antagonists","volume":"217","author":"Garthwaite","year":"2004","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib29","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1161\/CIRCULATIONAHA.109.895235","article-title":"Aldosterone receptor antagonists: effective but often forgotten","volume":"121","author":"Maron","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib30","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/ncpendmet0676","article-title":"Drug insight: eplerenone, a mineralocorticoid-receptor antagonist","volume":"4","author":"McManus","year":"2008","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/j.1875-9114.1993.tb02688.x","article-title":"Drug-induced gynecomastia","volume":"13","author":"Thompson","year":"1993","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib32","doi-asserted-by":"crossref","first-page":"B27","DOI":"10.1093\/eurheartj\/sur009","article-title":"Physiology of aldosterone and pharmacology of aldosterone blockers","volume":"13","author":"Struthers","year":"2011","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/clc.20324","article-title":"A comparison of the aldosterone-blocking agents eplerenone and spironolactone","volume":"31","author":"Struthers","year":"2008","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib34","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1043-2760(01)00527-6","article-title":"Nuclear receptor coregulators: multiple modes of modification","volume":"13","author":"Hermanson","year":"2002","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib35","doi-asserted-by":"crossref","first-page":"31283","DOI":"10.1074\/jbc.M504098200","article-title":"A ligand-mediated hydrogen bond network required for the activation of the mineralocorticoid receptor","volume":"280","author":"Bledsoe","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1677\/JME-09-0031","article-title":"The mineralocorticoid receptor and its coregulators","volume":"43","author":"Yang","year":"2009","journal-title":"J Mol Endocrinol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib37","doi-asserted-by":"crossref","first-page":"3317","DOI":"10.1093\/emboj\/17.12.3317","article-title":"Antagonism in the human mineralocorticoid receptor","volume":"17","author":"Fagart","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib38","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1210\/me.2004-0537","article-title":"The ligand-dependent interaction of mineralocorticoid receptor with coactivator and corepressor peptides suggests multiple activation mechanisms","volume":"19","author":"Hultman","year":"2005","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib39","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nsmb939","article-title":"Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension","volume":"12","author":"Fagart","year":"2005","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib40","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1161\/01.CIR.0000091405.00772.6E","article-title":"Effects of eplerenone, enalapril, and eplerenone\/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study","volume":"108","author":"Pitt","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/nrcardio.2011.157","article-title":"Current challenges in the clinical management of hypertension","volume":"9","author":"Ruilope","year":"2012","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib42","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1161\/CIRCULATIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"117","author":"Calhoun","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib43","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib44","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.semnephrol.2011.09.005","article-title":"Use of diuretics in heart failure and cirrhosis","volume":"1","author":"Schrier","year":"2011","journal-title":"Semin Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib45","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib46","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrendo.2011.76","article-title":"A comprehensive review of the clinical aspects of primary aldosteronism","volume":"7","author":"Rossi","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib47","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","article-title":"Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension","volume":"31","author":"Colussi","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib48","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","article-title":"Cardiovascular outcomes in patients with primary aldosteronism after treatment","volume":"168","author":"Catena","year":"2008","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib49","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1038\/ajh.2010.169","article-title":"Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment","volume":"23","author":"Sechi","year":"2010","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib50","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1210\/jc.2008-2245","article-title":"Intrarenal hemodynamics in primary aldosteronism before and after treatment","volume":"94","author":"Sechi","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib51","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1161\/HYPERTENSIONAHA.113.01755","article-title":"Response to effectiveness of adrenalectomy and aldosterone antagonists for long-term treatment of primary aldosteronism","volume":"62","author":"Rossi","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib52","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/ndt\/gfs587","article-title":"Regression of left ventricular hypertrophy in patients with primary aldosteronism\/low-renin hypertension on low-dose spironolactone","volume":"28","author":"Ori","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib53","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1517\/14656566.9.4.509","article-title":"Spironolactone vs. eplerenone for the treatment of idiopathic hyperaldosteronism","volume":"9","author":"Karagiannis","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib54","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib55","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/01.HYP.0000258554.87444.91","article-title":"Clinical and genetic correlates of aldosterone-to-renin ratio and relations to blood pressure in a community sample","volume":"49","author":"Newton-Cheh","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib56","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/jhh.2008.27","article-title":"High plasma aldosterone and low renin predict blood pressure increase and hypertension in middle-aged Caucasian populations","volume":"22","author":"Meneton","year":"2008","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib57","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cjca.2012.03.010","article-title":"Resistant hypertension and aldosterone: an update","volume":"28","author":"Clark","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib58","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib59","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ahj.2004.12.005","article-title":"Effects of eplerenone versus losartan in patients with low-renin hypertension","volume":"150","author":"Weinberger","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib60","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/0002-9149(82)90390-3","article-title":"Increase in plasma aldosterone during prolonged captopril treatment","volume":"49","author":"Lijnen","year":"1982","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib61","first-page":"CD008169","article-title":"Spironolactone for hypertension","volume":"8","author":"Batterink","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib62","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","article-title":"Efficacy of low-dose spironolactone in subjects with resistant hypertension","volume":"16","author":"Nishizaka","year":"2003","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib63","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/HJH.0b013e328014954d","article-title":"Low-dose spironolactone in the management of resistant hypertension: a surveillance study","volume":"25","author":"Lane","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib64","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","article-title":"Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension","volume":"25","author":"Burgess","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib65","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/S0735-1097(03)00054-8","article-title":"Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients","volume":"41","author":"Flack","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib66","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","article-title":"Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension","volume":"41","author":"White","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib67","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","article-title":"Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients","volume":"40","author":"Krum","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib68","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jash.2008.05.005","article-title":"Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension","volume":"2","author":"Calhoun","year":"2008","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib69","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/HJH.0b013e3283551e98","article-title":"Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study","volume":"30","author":"Bobrie","year":"2012","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib70","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1161\/01.CIR.101.25.2981","article-title":"Left ventricular remodeling after myocardial infarction: pathophysiology and therapy","volume":"101","author":"Sutton","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib71","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1161\/CIRCULATIONAHA.111.067918","article-title":"Aldosterone, mineralocorticoid receptor activation, and cardiovascular remodeling","volume":"124","author":"Leopold","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib72","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.coph.2012.12.007","article-title":"Mineralocorticoid receptor antagonists for therapy of coronary artery disease and related complications","volume":"13","author":"Zwadlo","year":"2013","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib73","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1161\/01.CIR.82.5.1730","article-title":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group","volume":"82","author":"Swedberg","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib74","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","article-title":"Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism","volume":"25","author":"Brilla","year":"1993","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib75","doi-asserted-by":"crossref","first-page":"38911","DOI":"10.1074\/jbc.M103984200","article-title":"Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid receptor","volume":"276","author":"Le Menuet","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib76","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"Fraccarollo","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib77","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.110.163287","article-title":"Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function","volume":"57","author":"Lother","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib78","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2362.2004.01400.x","article-title":"Aldosterone antagonism in heart failure: improvement of cardiac remodelling, endothelial dysfunction and platelet activation","volume":"34","author":"Bauersachs","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib79","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/01.CIR.0000153800.09920.40","article-title":"Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload","volume":"111","author":"Kuster","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib80","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/HYPERTENSIONAHA.107.093450","article-title":"Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction","volume":"50","author":"Sartorio","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib81","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/eurjhf\/hfr129","article-title":"Aldosterone and cortisol predict medium-term left ventricular remodelling following myocardial infarction","volume":"13","author":"Weir","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib82","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1093\/eurjhf\/hfr093","article-title":"CONSENSUS to EMPHASIS: the overwhelming evidence which makes blockade of the renin-angiotensin-aldosterone system the cornerstone of therapy for systolic heart failure","volume":"13","author":"McMurray","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib83","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jacc.2007.03.062","article-title":"Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure","volume":"50","author":"Chan","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib84","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1161\/01.CIR.102.22.2700","article-title":"Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators","volume":"102","author":"Zannad","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib85","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1016\/j.jacc.2011.04.049","volume":"58","author":"Rossignol","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib86","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1161\/01.HYP.0000036399.80194.D8","article-title":"Aldosterone antagonist improves diastolic function in essential hypertension","volume":"40","author":"Grandi","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib87","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1093\/eurjhf\/hfn015","article-title":"Antiremodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results","volume":"11","author":"Boccanelli","year":"2009","journal-title":"Eur J Heart Fail"},{"issue":"919","key":"10.1016\/j.semnephrol.2014.04.005_bib88","first-page":"e1","article-title":"Effects of canrenoate plus angiotensin-converting enzyme inhibitors versus angiotensin-converting enzyme inhibitors alone on systolic and diastolic function in patients with acute anterior myocardial infarction","volume":"150","author":"Di Pasquale","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib89","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijcard.2011.11.076","article-title":"Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia","volume":"167","author":"Beygui","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib90","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/eurheartj\/ehn543","article-title":"Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials","volume":"30","author":"Ezekowitz","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib91","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.amjmed.2011.12.018","article-title":"Eplerenone is not superior to older and less expensive aldosterone antagonists","volume":"125","author":"Chatterjee","year":"2012","journal-title":"Am J Med"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib92","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/eurheartj\/ehq019","article-title":"Plasma aldosterone levels are associated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study","volume":"31","author":"Tomaschitz","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib93","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.amjcard.2005.10.017","article-title":"Impact of plasma aldosterone levels for prediction of in-stent restenosis","volume":"97","author":"Amano","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib94","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1210\/jc.2007-0393","article-title":"Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus","volume":"92","author":"Joffe","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib95","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.cjca.2012.04.014","article-title":"Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque","volume":"28","author":"Rita","year":"2012","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib96","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2215\/CJN.09421209","article-title":"A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima\u2013media thickness in nondiabetic hemodialysis patients","volume":"5","author":"Vukusich","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib97","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1097\/00005344-200306000-00019","article-title":"Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and atherosclerosis in apolipoprotein E-deficient mice","volume":"41","author":"Keidar","year":"2003","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib98","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1161\/01.CIR.0000015854.60710.10","article-title":"Mineralocorticoid receptor antagonism in experimental atherosclerosis","volume":"105","author":"Rajagopalan","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib99","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.tips.2005.01.006","article-title":"Angiotensin II, angiotensin II antagonists and spironolactone and their modulation of cardiac repolarization","volume":"26","author":"Delp\u00f3n","year":"2005","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib100","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1093\/eurheartj\/ehi478","article-title":"Spironolactone reduces fibrosis of dilated atria during heart failure in rats with myocardial infarction","volume":"26","author":"Milliez","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib101","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","article-title":"Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias","volume":"111","author":"Ouvrard-Pascaud","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib102","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1161\/CIRCULATIONAHA.108.805804","article-title":"Mineralocorticoid modulation of cardiac ryanodine receptor activity is associated with downregulation of FK506-binding proteins","volume":"119","author":"Gomez","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib103","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/hr.2010.277","article-title":"Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats","volume":"34","author":"Kimura","year":"2011","journal-title":"Hypertens Res"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib104","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/j.1540-8167.2006.00372.x","article-title":"Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure","volume":"17","author":"Shroff","year":"2006","journal-title":"J Cardiovasc Electrophysiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib105","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1093\/eurheartj\/ehr266","article-title":"Aldosterone promotes atrial fibrillation","volume":"33","author":"Reil","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib106","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","article-title":"Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib107","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1016\/S0002-9149(00)00729-3","article-title":"Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy","volume":"85","author":"Ramires","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib108","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1097\/HJH.0b013e3282e9a72d","article-title":"Spironolactone has antiarrhythmic activity in ischaemic cardiac patients without cardiac failure","volume":"25","author":"Shah","year":"2007","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib109","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1161\/CIRCHEARTFAILURE.109.899526","article-title":"Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies","volume":"3","author":"Bowling","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib110","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/eurheartj\/ehm091","article-title":"A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure","volume":"28","author":"Ahmed","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib111","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2008.05.047","article-title":"A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure","volume":"137","author":"Alper","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib112","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jama.2011.1967","article-title":"Serum potassium levels and mortality in acute myocardial infarction","volume":"307","author":"Goyal","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib113","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s11906-007-0019-1","article-title":"The metabolic syndrome in primary aldosteronism","volume":"9","author":"Fallo","year":"2007","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib114","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ahj.2010.04.024","article-title":"Effect of eplerenone versus spironolactone on cortisol and haemoglobin A(c) levels in patients with chronic heart failure","volume":"160","author":"Yamaji","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib115","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s00125-008-0972-5","article-title":"Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles","volume":"51","author":"Swaminathan","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib116","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","article-title":"Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure","volume":"115","author":"Guder","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib117","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/ki.2011.48","article-title":"Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease","volume":"79","author":"Bertocchio","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1523-1755.2004.00701.x","article-title":"Aldosterone in the development and progression of renal injury","volume":"66","author":"Hollenberg","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib119","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1046\/j.1523-1755.2003.00340.x","article-title":"The June 2003 Barry M. Brenner Comgan lecture. The future of renoprotection: frustration and promises","volume":"64","author":"Schieppati","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib120","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1007\/s11906-011-0202-2","article-title":"Mineralocorticoid receptor blockade in chronic kidney disease","volume":"13","author":"Volk","year":"2011","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib121","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIRCULATIONAHA.105.539122","article-title":"Increased expression of mineralocorticoid effector mechanisms in kidney biopsies of patients with heavy proteinuria","volume":"112","author":"Quinkler","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib122","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2215\/CJN.00240106","article-title":"Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes","volume":"1","author":"Epstein","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib123","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","article-title":"Change in proteinuria after adding aldosterone blockers to ace inhibitors or angiotensin receptor blockers in CKD: a systematic review","volume":"51","author":"Bomback","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib124","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2215\/CJN.04750908","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis","volume":"4","author":"Navaneethan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib125","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","article-title":"Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease","volume":"70","author":"Bianchi","year":"2006","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib126","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1161\/01.HYP.0000044937.95080.E9","article-title":"Effectiveness of aldosterone blockade in patients with diabetic nephropathy","volume":"41","author":"Sato","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib127","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","article-title":"Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study","volume":"28","author":"Rossing","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib128","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","article-title":"Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the eplerenone post-acute myocardial infarction heart failure efficacy and survival study","volume":"125","author":"Rossignol","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib129","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/0016-5085(92)91730-R","article-title":"Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites","volume":"102","author":"Sungaila","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib130","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib131","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2125.2008.03205.x","article-title":"Spironolactone use and the risk of upper gastrointestinal bleeding: a population-based case-control study","volume":"66","author":"Gulmez","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib132","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib133","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","article-title":"Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study","volume":"351","author":"Juurlink","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib134","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejim.2011.04.008","article-title":"Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic","volume":"22","author":"Goland","year":"2011","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib135","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1001\/archinte.167.18.1930","article-title":"Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials","volume":"167","author":"Phillips","year":"2007","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib136","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1592\/phco.30.1.1","article-title":"Association of aldosterone concentration and mineralocorticoid receptor genotype with potassium response to spironolactone in patients with heart failure","volume":"30","author":"Cavallari","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib137","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","article-title":"PEARL-HF Investigators. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial","volume":"32","author":"Pitt","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib138","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1345\/aph.1H520","article-title":"Laboratory\u00a0evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia?","volume":"41","author":"Raebel","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib139","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","volume":"62","author":"Eschalier","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib140","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/01.hjh.0000226205.65442.f2","article-title":"Investigation of aldosterone-synthase inhibition in rats","volume":"24","author":"Menard","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib141","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1126\/science.289.5476.119","article-title":"Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy","volume":"289","author":"Geller","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib142","doi-asserted-by":"crossref","first-page":"4300","DOI":"10.1021\/jm1002827","article-title":"Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines","volume":"53","author":"Arhancet","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib143","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/HYPERTENSIONAHA.107.103580","article-title":"A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity","volume":"51","author":"Dietz","year":"2008","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib144","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.bbrc.2010.04.149","article-title":"Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity","volume":"396","author":"Matsui","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2010.03.018","article-title":"The L-, N-, and T-type triple calcium channel blocker benidipine acts as an antagonist of mineralocorticoid receptor, a member of nuclear receptor family","volume":"635","author":"Kosaka","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib146","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.1021\/jm100506y","article-title":"Discovery of novel cyanodihydropyridines as potent mineralocorticoid receptor antagonists","volume":"53","author":"Arhancet","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib147","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib148","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"Chem Med Chem"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib149","doi-asserted-by":"crossref","first-page":"5979","DOI":"10.1021\/jm100505n","article-title":"Discovery of (3S, 3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3, 3a, 4, 5-tetrahydro-2H-b enzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy","volume":"53","author":"Meyers","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib150","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1254\/jphs.10285FP","article-title":"SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity","volume":"115","author":"Nariai","year":"2011","journal-title":"J Pharmacol Sci"},{"issue":"Suppl","key":"10.1016\/j.semnephrol.2014.04.005_bib151","first-page":"772","article-title":"Cardiorenal protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical model of hypertension and diastolic heart failure [abstract]","volume":"33","author":"Delbeck","year":"2012","journal-title":"Eur Heart J"},{"issue":"Suppl","key":"10.1016\/j.semnephrol.2014.04.005_bib152","first-page":"7","article-title":"Pronounced cardiac protection by BAY 94-8862, a novel non-steroidal mineralocorticoid receptor antagonist in a preclinical rat model of heart failure [abstract]","volume":"32","author":"Albrecht-Kuepper","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib153","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib154","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1093\/ndt\/gfs388","article-title":"Aldosterone synthase inhibition in humans","volume":"28","author":"Azizi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib155","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1161\/CIRCULATIONAHA.104.521625","article-title":"Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage","volume":"111","author":"Fiebeler","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib156","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","article-title":"Prerequisite for cardiac aldosterone action: mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart","volume":"92","author":"Lomb\u00e8s","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib157","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/HJH.0b013e32835d6d49","article-title":"Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism","volume":"31","author":"Amar","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib158","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/ki.2009.9","article-title":"Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt","volume":"75","author":"Lea","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib159","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","article-title":"Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: a comparison with spironolactone","volume":"29","author":"Mulder","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib160","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1097\/HJH.0b013e32833c2197","article-title":"FAD286, an aldosterone synthase inhibitor, reduced atherosclerosis and inflammation in apolipoprotein E-deficient mice","volume":"28","author":"Gamliel-Lazarovich","year":"2010","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib161","doi-asserted-by":"crossref","first-page":"A61","DOI":"10.1016\/S0735-1097(10)60584-0","article-title":"Hormonal and electrolyte responses to the aldosterone synthase inhibitor lCI699 in sodium depleted healthy subjects","volume":"55","author":"Menard","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib162","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/HJH.0b013e328363570c","article-title":"Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy","volume":"31","author":"Schumacher","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib163","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib164","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1751-7176.2012.00667.x","article-title":"The effects of aldosterone synthase inhibition on aldosterone and cortisol in patients with hypertension: a phase II, randomized, double-blind, placebo-controlled, multicenter study","volume":"14","author":"Andersen","year":"2012","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib165","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/jch.12051","article-title":"Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension","volume":"15","author":"Karns","year":"2013","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib166","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib167","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bmcl.2010.11.040","article-title":"N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2)","volume":"21","author":"Zimmer","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib168","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/01.fjc.0000197539.12685.f5","article-title":"Inhibitory effect of efonidipine on aldosterone synthesis and secretion in human adenocarcinoma (H295R) cells","volume":"47","author":"Imagawa","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib169","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ejphar.2008.02.001","article-title":"Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R","volume":"584","author":"Akizuki","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib170","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejphar.2008.12.041","article-title":"Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R","volume":"605","author":"Isaka","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib171","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1161\/HYPERTENSIONAHA.113.01102","article-title":"MicroRNA-24 is a novel regulator of aldosterone and cortisol production in the human adrenal cortex","volume":"62","author":"Robertson","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib172","doi-asserted-by":"crossref","unstructured":"Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Exp Opin Pharmacother. 2014;15:605-21.","DOI":"10.1517\/14656566.2014.879117"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib173","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1056\/NEJMra0907219","article-title":"Use of diuretics in patients with hypertension","volume":"361","author":"Ernst","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib174","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2215\/CJN.06330612","article-title":"Effect of spironolactone and amiloride on thiazolidinedione-induced fluid retention in South Indian patients with type 2 diabetes","volume":"8","author":"Viswanathan","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1161\/01.HYP.0000022570.02119.75","article-title":"Amiloride, a specific drug for hypertension in black people with T594M variant?","volume":"40","author":"Baker","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib176","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.amjhyper.2005.08.005","article-title":"Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics","volume":"19","author":"Rayner","year":"2006","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.semnephrol.2014.04.005_bib177","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/heart.88.5.475","article-title":"Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure","volume":"88","author":"Farquharson","year":"2002","journal-title":"Heart"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929514000473?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929514000473?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T12:24:23Z","timestamp":1746188663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929514000473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":177,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0270929514000473"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2014.04.005","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}